ssbdconference.org

  • 14-17 SEP 2023
  • Riyadh, Saudi Arabia
Registration
Registration

Abstract

abstract submission
KEY DATES: 

 

Call for Abstracts: 20 July 2023 
Deadline of Abstract Submission: 01 September 2023 
Conference Date: 14-17 September 2023 

Location: 

Crown Plaza RDC, Riyadh, Saudi Arabia. 

Awards: 

Awards will be given to the top 3 abstracts per category (senior and young investigators) and paper of the year chosen by the Scientific Committee. 

Abstract Topics: 

  • Bone Marrow Transplantation 
  • Leukemia / MDS / MPN 
  • Lymphoma 
  • Myeloma 
  • Thrombosis and Hemostasis 
  • Bone Marrow Failure 
  • Hemoglobinopathy 
  • Transfusion Medicine 
  • Other Benign Haematology Disorders 

Who Should Attend? 

Any researcher working or studying in Saudi Arabia is invited to submit his/her hematology related research (Physicians, Pathologists, Scientists, Trainees and Students). 

 

Submission Procedure: 

Abstracts shall be submitted via abstract page at the conference website to: ssbdconference.org. 

Rules and Regulations: 

  1. Abstracts must be submitted in English. 
  2. Studies have to be conducted in Saudi Arabia and GCC by practicing physician, scientist or student. 
  3. All studies related to hematology, including basic science, translation or clinical research, are eligible.
  4. Studies have to be completed in the preceding year, 2022-2023. No studies “in progress” will be accepted. 
  5. Both published and unpublished studies are eligible. 

 

Selection Criteria: 

  • Abstracts will be evaluated through a blind review process and scored based upon the international criteria. 
  • Accepted abstracts will be selected for either Oral or Poster presentations. 
  • Top 3 abstracts per category (senior and young investigators) and paper of the year chosen by the Scientific Committee will be awarded. 

 

Abstract Format: 

Abstracts should be limited to a maximum of 1000 words. 

All abstracts must include the following: (Please refer to the attached template) 

  • Title of abstract 
  • Authors and their affiliating hospitals (Please indicate the name of the presenter). 
  • Introduction 
  • Methods 
  • Results 
  • Conclusions 

 

 Presentation 

Oral presentation or poster presentation. 

ABSTRACT SUBMISSION DEADLINE:
01st September 2023 

 

Please note that you must organize and submit your abstract using this template. Please do not use all CAPS. Please submit your abstract by uploading file in WORD FORMAT to abstract page at conference site 

ssbdconference.org 

ABSTRACT BODY 

The abstract must not exceed 1000 words (including tables). Your abstract must include a title, list of authors and affiliations, and content including a concise introduction, statement of the main thesis, summary and conclusion. The format for trial/study abstracts should include the following sections: objective, rationale, methodology, results and conclusions. 

abstract template

 

Characterizing non-hematopoietic progenitor cell populations from human umbilical cord blood: implications for cord blood banking 

Halpenny M 1, Yang L1, Birch P 1(Presenter), Martin L1, Fung Kee Fung K 2, Haebe J 2, Li C3, Allan DS 3, Giulivi A 1, Goldman M1 

1The Canadian Blood Services Stem Cell Processing Laboratory, Ottawa; 2Department of Obstetrics, The Ottawa Hospital, and 3 Ottawa Health Research Institute 

Background: Banking of human umbilical cord blood is increasing worldwide due to the increasing need to find alternative stem cell sources for hematopoietic transplantation and for their emerging role in regenerative therapy. The Canadian Blood Services Ottawa Stem Cell laboratory provides stem cell processing services to multiple clinical sites, is FACT-accredited, and processes human stem cell products in accordance with GMP guidelines. In anticipation of an increasing role of Canadian Blood Services in cord blood banking, we sought to characterize progenitor cell populations in human umbilical cord blood. 

 

Methods: Following informed consent, human umbilical cord blood (UCB) was collected following vaginal delivery or elective Caesarean section using a commercially available cord blood collection kit. CBUs were transported from The Ottawa Hospital to Canadian Blood Services in standard boxes at ambient temperature and processed within 24 hours of collection. Mononuclear cells were isolated, enumerated and cultured using previously published methods to characterize mesenchymal stem cells (MSC), endothelial-like vascular progenitor cells (VPC) (Endocult, Stem Cell Technologies), hematopoietic stem cells colony-forming units (Methocult, Stem Cell Technologies), and neural stem cells (NSC) (Stem Cell Technologies). In addition, a bioarchiving and cryopreservation system was designed to provide a reliable inventory database to track all research samples from laboratory freezers to final disposition. 

 

Results: Cord blood samples (n=12) were processed according to our standard protocol. All samples 

yielded CFU , CFU and CFU 

………………Column Break………………. Samples (n=4/12) also yielded VPC clusters which were 

 

E GM, GEMM 

CD45+CD14+ and VEGFR2+. In addition, cells/colonies with MSC morphology and immunophenotype (CD90+, CD105+ and CD34/45-) were isolated (n=2/4). These UCB MSC-like cells, could undergo multiple passages and differenciate into different connective tissue lineages such as bone, carilage, and adipose tissues. 

 

Conclusion: Research CBUs can be effectively collected, transported, processed and stored safely in a clinical stem cell laboratory using standard protocols and a bioarchive system. Initial cord blood units processed at our facility retain hematopoietic characteristics required for hematopoietic stem cell transplan 

abstract submission